ALR Technologies Announces Sales Guidance for Q4 2022, Q1 2023, and Completion of the GluCurve Pet CGM Manufacturing Agreement

Rhea-AI Summary

ALR Technologies SG Ltd. (ALRT) has finalized a long-term manufacturing and supply agreement with Infinovo Medical for the Continuous Glucose Monitor hardware used in the GluCurve Pet CGM. This deal grants ALRT exclusive global rights to distribute this CGM in the animal health sector. For December 2022, ALRT anticipates sales between $145,000 and $155,000, with expected Q1 2023 sales between $450,000 and $600,000. ALRT will showcase the GluCurve Pet CGM at CES and VMX in January, aiming to boost market awareness.

Positive

• Exclusive distribution rights for CGM hardware in animal health market.
• Projected sales growth with December sales estimated at $145,000-$155,000 and Q1 2023 at $450,000-$600,000.
• Increased production capacity expected to boost sales throughout 2023.

Negative

• None.

SINGAPORE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM. The agreement gives ALRT the exclusive global rights to distribute the CGM hardware in the animal health market.

Additionally, the Company announces it anticipates December and fourth quarter of 2022 sales to be in the range of $145,000 and $155,000. The Company expects Q1 2023 sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.

“December reflects a turning point for ALRT as we look to close out the fiscal year with our first quarter of meaningful sales, along with an attractive gross profit,” said Sidney Chan, Chairman and CEO of ALRT. “We will be exhibiting the GluCurve Pet CGM at CES January 5^th-8^th and VMX (Veterinary Meeting and Expo) January 14^th-18^th which should bolster awareness around the Company and GluCurve. The number of available units will increase quarter over quarter throughout 2023 resulting in a significant rise in sales as it will enable our distribution partner, Covetrus, to launch GluCurve throughout the US, EU, and other key markets.”

About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.

In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.

More information about ALRT can be found at www.alrt.com and https://sg.alrt.com.

Investor Contact
Investor Relations: ir@alrt.com
Animal Health Inquiries: animalhealth@alrt.com
Media: Media@alrt.com
US: +1 804 554 3500
Singapore: +65 3129 2924

ALR Technologies SG Ltd. Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future sales and revenues, expected levels of product inventory and demand, strategy for customer retention, growth, product distribution, market penetration and expansion, financial results and reserves, and strategy for risk management. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: failure to generate anticipated company and product awareness, inability to maintain production capacity sufficient to meet customer demand for product, increased manufacturing costs, decreases in product market price, economic, regulatory, practical or other impediments to anticipated market expansion, and insufficient product demand. More information on these risks and other potential factors that could affect our business, reputation, results of operations, financial condition, and stock price is included in our filings with the SEC and subsequent filings. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. 

FAQ

What recent agreement did ALRT announce regarding CGM hardware?

ALRT announced a long-term manufacturing and supply agreement with Infinovo Medical for the CGM hardware used in the GluCurve Pet CGM.

What are ALRT's expected sales figures for December 2022?

ALRT anticipates December 2022 sales to be in the range of $145,000 to $155,000.

What are the projected sales for ALRT in Q1 2023?

ALRT expects Q1 2023 sales to be between $450,000 and $600,000, possibly higher due to increased production capacity.

When and where will ALRT showcase the GluCurve Pet CGM?

ALRT will exhibit the GluCurve Pet CGM at CES from January 5-8 and at VMX from January 14-18.

What does the agreement with Infinovo allow ALRT to do?

The agreement gives ALRT exclusive global rights to distribute the CGM hardware in the animal health market.